Mutations truncating the EP300 acetylase in human cancers

By S. Gayther, Sarah J. Batley, Lori Linger, Andrew J. Bannister, K. Thorpe, S. Chin, Y. Daigo, P. Russell, Annie Wilson, H. Sowter and 4 more. Nature Genetics, 2000

625 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/e3bab48488f0e71fb71ea8dd50af8ae23b052432

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

p300/CBP and cancer (2004, background): “The analysis was extended in our laboratory to include a total of 222 cancer samples (Gayther et al., 2000; Ozdag et al., 2002).”
Histone deacetylases and cancer: causes and therapies (2001, background): “In these cases, the second allele was frequently delete”
Cancer epigenetics reaches mainstream oncology (2011, background): “Finally, whereas colorectal, gastric, breast and pancreatic tumors show missense mutations of EP300 , monoallelic loss of KAT5 (encoding lysine acetyltransferase-5) increases the potential for malignant transformatio”
Endocrine-responsive breast cancer and strategies for combating resistance (2002, background): “Paradoxically, these mutations seem to cause loss of function, indicating that CBP is a tumour-suppressor protei”
Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours (2002, background): “A few genetic alterations affecting genes of these three groups have been described and are worth mentioning: truncating mutations of hSNF5/INI1 in paediatric cancers [56]; inactivating mutations of the histone acetyltransferases p300 in solid tumours [57] and CBP in families with the Rubinstein–Tay”
Histone Modifications and Cancer. (2016, background): “The resulting loss of heterozygosity implicates them as tumor suppressors (Muraoka et al. 1996; Gayther et al. 2000; for more on the characterization of tumor-suppressor genes, see Baylin and Jones 2014).”
Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials (2019, background): “Missense point mutations in p300 are found in colorectal adenocarcinoma, gastric adenocarcinoma and breast cancer with quite low incidences.(186,187) Rare inactivating mutations in CBP and PCAF have only been identified in cancer cell lines but not primary tumors.”
Aberrant epigenetic landscape in cancer: how cellular identity goes awry. (2010, neutral): “H2BK15 mutation loss breast; CRC Gayther et al. (2000) 10700188”
CBP/p300 in cell growth, transformation, and development. (2000, background): “Muroaka et al. (1996) identified p300 missense mutations associated with loss of heterozygosity in tumors from two patients, one with colorectal and the other with gastric carcinoma, and Gayther et al. (2000) recently reported five additional examples.”
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer (2002, neutral): “gov/cancer_information/cancer_type/breast/">breast cancers , and glioblastoma”